The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year's Miami Miles for Melanoma 5K will take place on Sunday,...
Blushwood Health is a global botanical wellness brand delivering independently tested EBC-46 extracts with medical oversight, transparent sourcing, and rigorous quality assurance. STOCKHOLM, Jan. 30, 2026 /PRNewswire-PRWeb/ -- Blushwood Health is a global botanical wellness company...
New research highlighted by Lovingfeel shows that short, positive exchanges are becoming a defining pattern across online social platforms, reflecting a shift toward lighter, emotionally supportive digital interactions. GIBRALTAR, Jan. 30, 2026 /PRNewswire-PRWeb/ -- Online communication...
JACANA achieves milestone first export of medical cannabis from Jamaica to Cayman Islands, introducing patients to organically cultivated, sun-grown Jamaican cannabis. ST ANN, Jamaica and GEORGE TOWN, Cayman Islands, Jan. 30, 2026 /PRNewswire-PRWeb/ -- JACANA, a vertically integrated...
Care Advantage, Inc., one of the largest privately owned home care companies in the Mid-Atlantic, announced today that it has completed the acquisition of Neighborly Home Care's Wilmington and Georgetown, Delaware locations. The transaction reinforces Care Advantage's ongoing commitment...
The New Jersey medical practice has expanded to Bergen County, with Dr. Basil Kurdali serving as Medical Director. BERGEN COUNTY, N.J., Jan. 30, 2026 /PRNewswire-PRWeb/ -- Visco Spine & Joint Center, one of New Jersey's leading providers of non-surgical treatment for spine and joint...
Primary Health Partners has appointed Courtney Willis as Chief Growth Officer to lead strategic expansion of its Direct Primary Care model across Oklahoma. With a strong background in healthcare leadership, Willis will drive multi-channel growth, employer partnerships, and data-driven...
Franchise Now, a franchise funding firm dedicated to accelerating the franchise lending process, today announced the launch of their DreamStart™ Funding Program – a revolutionary approach designed to drastically reduce the traditional waiting period for borrowers. FORT WORTH, Texas, Jan....
Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; first stage of multi-phase MotifAi Assistant...
Fully managed PRO services, reporting-ready data for reimbursement and quality programs, and a growing national benchmarking registry set CODE apart as healthcare organizations faced increasing reporting and reimbursement risk. MINNEAPOLIS, Jan. 29, 2026 /PRNewswire-PRWeb/ -- In 2025,...
Collaboration enhances life science lab connectivity by integrating automated imaging and detection systems into research workflows SAN JOSE, Calif., Jan. 29, 2026 /PRNewswire-PRWeb/ -- Molecular Devices, LLC., a leading provider of high‑performance life science solutions and an operating...
Measurable burnout reduction, nurse and physician engagement, HCAHPS-integrated insights, national partnerships, and federal workforce alignment position SE Healthcare as a category leader in workforce resilience CHARLESTON, S.C., Jan. 29, 2026 /PRNewswire-PRWeb/ -- SE Healthcare, a...
More than $2.75 million in grants have been awarded to community partners through CDP's California Wildfires Recovery Fund over the past year WASHINGTON, Jan. 29, 2026 /PRNewswire-PRWeb/ -- One year after the Eaton and Palisades Fires burned across Greater Los Angeles in January 2025, the...
Dr. Regan, who previously worked as a fractional Surgicalist surgeon through Synergy, will lead the organization's expansion of its general surgery service line. SAN DIEGO, Jan. 29, 2026 /PRNewswire-PRWeb/ -- Synergy Health Partners, a national leader in innovative surgical staffing and...
SAN FRANCISCO, Jan. 28, 2026 /PRNewswire-PRWeb/ -- Miss.Smriti Kirubanandan has joined Innovaccer as Managing Director, where she will lead the company's Gravity platform, focusing on enterprise-scale adoption of artificial intelligence and data-driven transformation across healthcare....
Hosein will participate on the AI & Healthcare panel, joining leading voices at the intersection of artificial intelligence, longevity science, and healthcare transformation. Among the panelists is Joe Betts-LaCroix, CEO of Retro Biosciences, a longevity-focused biotechnology company...
SightMD, a leading multi-state ophthalmology and eye-care network, is proud to announce that 26 of its physicians have been named to the 2026 Castle Connolly Top Doctors® list, a prestigious national recognition honoring physicians who exemplify excellence in clinical care, professional...
Milestone reflects growing demand among health systems, clinicians and patients for evidence-based, root-cause approaches to chronic disease treatment, remission and prevention. ST. LOUIS, Jan. 28, 2026 /PRNewswire-PRWeb/ -- More than 10,000 physicians and health professionals worldwide...
The partnership brings privacy-first attribution to Connected TV, helping healthcare marketers measure impact, protect patient privacy, and activate a channel once considered off-limits. SAN FRANCISCO, Jan. 28, 2026 /PRNewswire-PRWeb/ -- Freshpaint, a healthcare marketing performance...
Real Stories of Addiction and Hope, a documentary by Emmy Award–winning producer Adam Oberfeld, will be screened on February 19, 2026, at The Gordon Center for Performing Arts in Owings Mills, Maryland. The event will feature a live panel discussion with individuals featured in the film,...
The World Health Organization (WHO) Member States this week advanced their negotiations on the Pathogen Access and Benefit‑Sharing (PABS) system in a resumed session of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement. The PABS system is a core element of the agreement adopted by the World Health Assembly (WHA) in May 2025.
During the session held on 20–22 January 2026, Member States continued text‑based negotiations on outstanding issues in the draft annex and exchanged views aimed at narrowing differences and identifying areas of convergence.
“I am encouraged by the progress we have made in several areas, with signs of emerging consensus for some parts of the Pathogen Access and Benefit‑Sharing system,” said IGWG Bureau co‑chair Ambassador Tovar da Silva Nunes, of Brazil. “As we look ahead to the fifth session, the focus will be on the outstanding, complex issues. The resumed session has helped us gain a clearer picture of where we stand.”
Established by the WHA, the IGWG is tasked, as a priority, with drafting and negotiating the PABS system, which is intended to enable safe, transparent and accountable sharing of pathogens with pandemic potential and their genetic sequence information, alongside the fair and equitable sharing of benefits arising from their use, including vaccines, therapeutics and diagnostics.
The resumed session was held following a request by Member States to extend the fourth meeting of the IGWG, which convened in December 2025.
“Member States have engaged in constructive discussions this week," said IGWG Bureau co-chair Mr Matthew Harpur, of the United Kingdom. "As we make progress towards the May deadline, I am encouraged by their willingness to work together and bridge differences to deliver an effective Pathogen Access and Benefit‑Sharing system."
Further meetings of the IGWG are scheduled in the coming months as Member States continue their negotiations.
“A strong Pathogen Access and Benefit‑Sharing system will be a cornerstone of a safer and more equitable world,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “I thank countries for their commitment to multilateral solutions.”
The outcome of IGWG’s work will be submitted to the Seventy‑ninth World Health Assembly in May 2026 for its consideration.
Access to treatment for leprosy is essential to global efforts to eliminate leprosy, says the World Health Organization (WHO) ahead of World Leprosy Day, to be observed on 25 January.
Leprosy is an infectious disease caused by a type of bacteria, Mycobacterium leprae, and is one of the oldest diseases known to humanity. The disease predominantly affects the skin and peripheral nerves. Left untreated, the disease may cause progressive and permanent disabilities and causes stigma and social isolation. However, the disease can be cured with multidrug therapy (MDT).
Efforts to eliminate leprosy have been leading to reductions in the number of new cases in many areas; of the 188 countries, areas or territories that submitted data in 2024, 55 reported zero cases. But still 172 717 new cases were detected worldwide and reported to WHO in the same year.
Many partners, including pharmaceutical companies such as Novartis, have been strong supporters of efforts to eliminate leprosy. WHO has collaborated with Novartis since 2000 to provide MDT and clofazimine, free of cost, to all leprosy patients worldwide. This partnership remains one of the most sustained pharmaceutical donation programmes in global health.
Marking 25 years of partnership, WHO and Novartis have extended a Memorandum of Understanding (MoU) for an additional 5 years (2026−2030). The extension makes provision for continued supply of MDT and also includes funding for procurement and distribution of single dose rifampicin (SDR) for post-exposure prophylaxis (PEP).
“The unwavering commitment of partners like Novartis over the past quarter-century has been foundational to the progress made against leprosy,” said Dr Jeremy Farrar, WHO Assistant Director-General for Health Promotion, Disease Prevention and Care. “Their steadfast support in ensuring free access to treatment has helped transform millions of lives and moved us closer to a world free from this ancient disease. This enduring collaboration exemplifies the power of global solidarity in health – a reminder that, together, we can overcome even the oldest and most entrenched health challenges when science, equity, and partnership align.”
Availability of free MDT has made it possible to cure the disease, prevent disabilities, mitigate stigma, and has enabled affected individuals to continue working and leading normal lives. Additionally, clofazimine has ensured the treatment of lepra reactions, which are characterized by sudden, severe inflammatory episodes, leading to disabilities, if left untreated.
“Leprosy is one of the oldest infectious diseases known to humanity and combatting it has been part of our company’s history since discovering the first effective cure,” said Dr Lutz Hegemann, President of Global Health at Novartis. “Over the last 25 years, we have reached millions of patients together with WHO, and we are committed to going further to pursue our vision of a world free of leprosy.”
While significant progress has been made, sustaining and building on this momentum requires political commitment, community engagement and continued collaboration and partnership.
The theme for this year’s World Leprosy Day is “Leprosy is curable, the real challenge is stigma”.
This year also marks the 25th anniversary of Mr Yohei Sasakawa’s work as the WHO Goodwill Ambassador for Leprosy Elimination. He said, “One of the most stubborn challenges that I encounter on my travels is the social stigma attached to leprosy, which can be more problematic than the disease itself, and which can persist beyond the end of treatment. This is particularly true for people who have been left with residual disabilities as a result of leprosy. They may face various forms of discrimination, including forced divorce, lost educational opportunities and unfair dismissal. Even after being cured, they endure the unending pain of social exclusion.”
As leprosy is one of the target diseases under the broader umbrella of Neglected Tropical Diseases (NTDs), this work also supports the unified global effort towards a world free of NTDs. Learn more about the collective action and join our campaign on World NTD Day 2026 on 30 January.
The NTD Roadmap 2021-2030 aims at elimination of leprosy (interruption of transmission). The Global Leprosy Strategy 2021–2030 underpinning the Roadmap, shifts the paradigm beyond the achievement of ‘elimination of leprosy as a public health problem’ toward interruption of transmission and elimination of leprosy disease. Contact screening along with scale-up of preventive chemotherapy and mitigation of stigma and discrimination constitute key pillars of this strategy. Beyond working to ensure that every person affected by leprosy is detected early and treated promptly, WHO leads efforts to combat the discrimination that persons affected by leprosy too often face.
Today, the conflict in Sudan reaches its 1000th day, with over 20 million people requiring health assistance and 21 million desperately needing food.
Nearly three years of continuous violence, severe access constraints, and reduced funding have turned Sudan into the worst humanitarian crisis globally. An estimated 33.7 million people will need humanitarian aid this year.
The health system has been severely damaged by ongoing fighting, increasingly deadly attacks on health care, mass displacement, lack of essential medical supplies, and shortages of health personnel and funding. Despite sustained efforts by WHO and partners to restore and revive health services across the country, more than one third of health facilities (37%) remain non-functional, depriving millions of people of essential and lifesaving health services.
Since the start of the conflict in April 2023, WHO has verified 201 attacks on health care, resulting in 1858 deaths and 490 injuries. These attacks, which violate international humanitarian law, undermine access to lifesaving care and put health care workers, patients and caregivers at grave risk.
“One thousand days of conflict in Sudan have driven the health system to the brink of collapse. Under the strain of disease, hunger and a lack of access to basic services, people face a devastating situation,” said WHO Representative in Sudan, Dr Shible Sahbani. “WHO is doing what we can, where we can, and we know we are saving lives and rebuilding the health system. Despite the challenges, we are also working on recovery of the health system.”
The level of displacement is unprecedented. An estimated 13.6 million people are currently displaced, making Sudan the largest displacement crisis in the world. Fueled by poor living conditions, overcrowding in displacement sites, disrupted health and water, sanitation and hygiene services, and a breakdown of routine immunization, disease outbreaks are spreading, compounding the crisis. WHO is currently supporting the response to outbreaks of cholera, dengue, malaria, and measles, with cholera being reported from all 18 states, dengue from 14 states, and malaria from 16 states. Access to preventive and curative care, including for the management of chronic conditions and severe malnutrition, remains limited.
WHO works with Sudan’s Federal and State Ministries of Health and partners to improve access to critical health services across Sudan and rehabilitate the health system. Since the start of the conflict in April 2023, WHO has delivered 3378 metric tons of medicines and medical supplies worth about US$ 40 million, including diagnostic supplies, treatments for malnutrition, and diseases such as cholera, malaria, dengue, and emergency surgery, to 48 health partners for lifesaving operations. About 24 million people have received cholera vaccinations, and WHO has supported the country to introduce and scale up malaria vaccines. Additionally, more than 3.3 million people have accessed health care at WHO-supported hospitals, primary health care facilities, and temporary mobile clinics. More than 112 400 children with severe acute malnutrition with medical complications have received treatment at functional stabilization centres, all of which receive lifesaving WHO nutrition supplies. State and National public health laboratories have been equipped and strengthened to confirm disease outbreaks and enable a rapid response.
“As the relentless conflict renders some areas inaccessible, particularly in the Darfur and Kordofan regions, the population’s health needs continue to increase,” Dr Sahbani said. “To meet these mounting needs and prevent the crisis from spiraling out of hand, WHO and humanitarian partners require safe and unimpeded access to all areas of Sudan, and increased financial resources.”
Ultimately, WHO calls parties to the conflict to urgently work towards a ceasefire and peace for the people of Sudan.